Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Primary Lymphoid Organs01:16

Primary Lymphoid Organs

4.9K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
4.9K
Secondary Lymphoid Organs01:15

Secondary Lymphoid Organs

2.4K
Secondary organs, including lymph nodes, the spleen, and mucosa-associated lymphoid tissue (MALT), work harmoniously to protect us from disease and infection.
The spleen is a vital organ in the lymphatic system, nestled in the upper left side of the abdomen. It is composed of two primary regions: the red pulp and the white pulp, each having distinct functions. The red pulp performs a significant role in blood filtration. It efficiently purges the blood of old or damaged red blood cells and...
2.4K
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

1.5K
Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...
1.5K
Disorders of Leukocytes01:27

Disorders of Leukocytes

1.1K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
1.1K
Cells of the Adaptive Immune Response01:23

Cells of the Adaptive Immune Response

3.8K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
3.8K
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

1.2K
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Pathologie (Heidelberg, Germany)·2026
Same author

Evaluation of prognostic factors and outcomes in primary versus secondary myeloid sarcoma.

Human pathology·2026
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

The genetic landscape of extramedullary plasmacytoma: a comparative analysis with extramedullary disease of multiple myeloma.

Haematologica·2026
Same author

CD70/CD27 signaling promotes the pathogenesis of multiple myeloma and represents a promising therapeutic target.

Leukemia·2026
Same author

Clinical outcome of biomarker-guided therapies in adult neuro-oncology patients: An update from the Tübingen molecular tumor board cohort.

Neuro-oncology advances·2026
Same journal

Pathodashboard: an epidemiological atlas for tumour diagnostics.

Pathologie (Heidelberg, Germany)·2026
Same journal

Pathologie (Heidelberg, Germany)·2026
Same journal

[Genetic diagnostics].

Pathologie (Heidelberg, Germany)·2026
Same journal

[Guideline development for MRD diagnostics in AML as a blueprint for solid tumors].

Pathologie (Heidelberg, Germany)·2026
Same journal

[Therapy of melanoma : Current standards and future perspectives].

Pathologie (Heidelberg, Germany)·2026
See all related articles

Related Experiment Video

Updated: Sep 2, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.5K

[EBV-associated lymphoproliferative disorders].

Mathis Overkamp1,2, Leticia Quintanilla-Martinez1,2, Falko Fend3,4

  • 1Institut für Pathologie und Neuropathologie und Referenzzentrum für Hämatopathologie, Universitätsklinikum Tübingen, Liebermeisterstraße 8, 72076, Tübingen, Deutschland.

Pathologie (Heidelberg, Germany)
|August 4, 2022
PubMed
Summary
This summary is machine-generated.

Epstein-Barr virus-associated lymphoproliferations (EBV-LPD) range from benign to malignant. This review clarifies diagnostic criteria for non-malignant EBV-LPD in various patient groups.

Keywords:
EBV latency typeEpstein-Barr-virus infectionsImmunologic deficiencyInfectious mononucleosisLymphoma

More Related Videos

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.3K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Related Experiment Videos

Last Updated: Sep 2, 2025

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines
06:38

Establishment of Epstein-Barr Virus Growth-transformed Lymphoblastoid Cell Lines

Published on: November 8, 2011

40.5K
An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection
09:43

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

9.3K
Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis
08:44

Separation of Immune Cell Subpopulations in Peripheral Blood Samples from Children with Infectious Mononucleosis

Published on: September 7, 2022

2.5K

Area of Science:

  • Pathology
  • Virology
  • Immunology

Background:

  • Epstein-Barr virus-associated lymphoproliferations (EBV-LPD) present a diverse spectrum, from self-limiting conditions to aggressive lymphomas.
  • The clinical and morphological variability of EBV-LPD, coupled with the high prevalence of Epstein-Barr virus (EBV) infections, necessitates precise diagnostic criteria in pathology.
  • Understanding EBV-LPD is crucial for accurate diagnosis and patient management, especially in differentiating benign from malignant forms.

Purpose of the Study:

  • To review the clinical and pathological features of non-malignant EBV-related lymphoproliferative disorders (LPD).
  • To discuss the current classification of EBV-LPD, considering both immunocompetent and immunosuppressed patients.
  • To highlight key diagnostic considerations for EBV-LPD, including cell origin and EBV latency types.

Main Methods:

  • Review of existing literature on EBV-LPD.
  • Analysis of clinical presentations and pathological characteristics of EBV-LPD.
  • Discussion of diagnostic criteria and classification systems for EBV-LPD.

Main Results:

  • EBV-LPD can originate from B-cells or T/NK-cells.
  • Identification of EBV latency type and patient's immune status are critical for differentiating EBV-LPD from malignant lymphoma.
  • Diagnosis of EBV+ T/NK-cell LPD requires consideration of clinical context and EBV detection in T- and NK-cells, with these being rare in Europe.

Conclusions:

  • Accurate diagnosis of EBV-LPD relies on integrating clinical information, pathological findings, and EBV-specific diagnostics.
  • Distinguishing non-malignant EBV-LPD from lymphoma is essential for appropriate treatment and patient outcomes.
  • Further research into EBV-LPD, particularly T/NK-cell variants, is warranted.